Core Insights - The global pharmaceutical industry is convening at CPHI Frankfurt 2025 from October 28–30, with Apeloa Pharmaceutical showcasing its technology-driven solutions [1] - Apeloa emphasizes its advanced technology platforms that enhance its CDMO services and API manufacturing capabilities [2] Technology Platforms - Apeloa's flow chemistry platform significantly reduces reaction time for a key cephalosporin intermediate by 99%, from 8 hours to under 5 minutes, while also decreasing Process Mass Intensity (PMI) by 53% and halving energy consumption [2] - The company offers high-purity linkers and comprehensive chemistry services to support ADC, targeted conjugation, and peptide drug development projects [3] Business Units - Apeloa provides end-to-end CDMO and global API solutions, leveraging its technology platforms to support global partners seamlessly [5] - The company specializes in monodisperse PEG synthesis, delivering high purity (≥98%) PEGs with a precise polydispersity index of 1.00, scalable from R&D to multi-kilogram production [6] Company Overview - Founded in 1989, Apeloa is a leading pharmaceutical subsidiary of Hengdian Group, recognized as one of China's top 2 API exporters and top 5 CDMO companies [7] - Apeloa's manufacturing sites are certified by major global regulators, having successfully passed 19 US FDA inspections since 2006, ensuring high-quality service for global partners [7] CDMO Services - Apeloa offers a comprehensive, one-stop CDMO service for the entire life cycle of new drug development and commercialization, enabling clients to expedite the delivery of affordable medications [8] - The company maintains a vertically integrated supply chain from intermediates to finished dosage forms (FDFs), supported by a robust R&D-to-commercialization framework [8]